Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 8,752 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 8,752 shares of Kestra Medical Technologies stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.60, for a total transaction of $197,795.20. Following the completion of the sale, the insider owned 206,995 shares in the company, valued at approximately $4,678,087. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ KMTS opened at $23.99 on Tuesday. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a 50-day moving average price of $22.62 and a two-hundred day moving average price of $22.48.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on KMTS. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. The Goldman Sachs Group cut their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average target price of $27.83.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of institutional investors have recently added to or reduced their stakes in KMTS. Seven Grand Managers LLC bought a new position in Kestra Medical Technologies during the 4th quarter valued at $2,652,000. Eventide Asset Management LLC raised its stake in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares in the last quarter. Summit Partners Public Asset Management LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter worth $9,282,000. UBS Group AG lifted its holdings in shares of Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares during the period. Finally, Jennison Associates LLC boosted its stake in Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after buying an additional 28,573 shares in the last quarter.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.